DOCIVYX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOCIVYX (DOCIVYX).
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
| Metabolism | Primarily metabolized by CYP3A4; undergoes oxidation of the tert-butyl group, followed by conjugation. |
| Excretion | Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment. |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 2-4 L/kg indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability 60-70% due to first-pass metabolism. |
| Onset of Action | IV: within 5-10 minutes; Oral: onset 30-60 minutes. |
| Duration of Action | Duration is 12-24 hours after IV dose; oral duration 6-12 hours due to absorption factors. |
| Molecular Weight | 521.47 |
75 mg/m2 intravenously over 1 hour every 3 weeks.
| Dosage form | SOLUTION |
| Renal impairment | CrCl ≥30 mL/min: No adjustment; CrCl <30 mL/min: Not recommended (no data). |
| Liver impairment | Child-Pugh A: 75 mg/m2; Child-Pugh B: Reduce to 50 mg/m2; Child-Pugh C: Not recommended. |
| Pediatric use | 75 mg/m2 intravenously over 1 hour every 3 weeks (approved for patients ≥2 years). |
| Geriatric use | No dose adjustment required based on age alone; monitor for increased toxicity. |
| 1st trimester | Avoid: Teratogenic effects observed in animal studies; no adequate human studies. Use only if benefit justifies risk. |
| 2nd trimester | Avoid: Potential fetal toxicity; consider alternative therapy. |
| 3rd trimester | Avoid: Risk of neonatal adverse effects (e.g., hypotension, respiratory depression) if used near term. |
Clinical note
Comprehensive clinical and safety monograph for DOCIVYX (DOCIVYX).
| Placental transfer | Crosses placenta in animal studies; likely in humans based on molecular weight and lipid solubility. Not quantified. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: Toxicity including fatalities related to hypersensitivity reactions, fluid retention, and neutropenia. Do not use if neutrophil count <1500 cells/mm3.
| Serious Effects |
Hypersensitivity to DOCIVYX or any componentSevere hepatic impairment (Child-Pugh C)Pregnancy (unless benefit outweighs risk in life-threatening conditions)
| Precautions | Severe hypersensitivity reactions require immediate discontinuation, Fluid retention including peripheral edema and pleural effusion, Severe neutropenia with increased infection risk, Severe cutaneous reactions, Hepatic impairment reduces clearance |
| Food/Dietary | Avoid grapefruit juice and grapefruit products due to CYP3A4 inhibition. Maintain adequate hydration but do not consume large amounts of grapefruit or Seville oranges. No other significant food interactions known. |
Loading safety data…
| L4 (Possibly Hazardous) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: high risk of neural tube defects (spina bifida, anencephaly), cleft palate, and cardiac malformations (ventricular septal defect). Second and third trimesters: increased risk of intrauterine growth restriction (IUGR), oligohydramnios, and fetal/neonatal myelosuppression. Late third trimester: risk of neonatal hemorrhage secondary to platelet dysfunction. |
| Fetal Monitoring | Maternal: complete blood count (CBC) with differential every 2 weeks, liver function tests (ALT, AST) and renal profile (serum creatinine) monthly, urine protein and blood pressure weekly to detect preeclampsia. Fetal: targeted ultrasound at 18–20 weeks for structural anomalies, serial growth scans (every 4 weeks) for IUGR, and nonstress test (NST) or biophysical profile (BPP) weekly from 32 weeks until delivery. |
| Fertility Effects | In females: ovarian suppression with reduced estrogen and progesterone levels, potentially transient amenorrhea and anovulation. In males: oligospermia or azoospermia with possible germ cell aplasia; effects are generally reversible 3–6 months after discontinuation based on small cohort studies. |
| Clinical Pearls | DOCIVYX is a novel antiviral agent with a narrow therapeutic index; monitor renal function closely as it is predominantly renally excreted. Administer with a full glass of water and avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) to prevent toxicity. Dose adjustment required for CrCl <30 mL/min. |
| Patient Advice | Take exactly as prescribed; do not skip doses or double up if missed. · Report any signs of nephrotoxicity: decreased urination, swelling, fatigue. · Avoid grapefruit juice and St. John's Wort while on this medication. · May cause dizziness; do not drive until you know how this drug affects you. · Complete full course even if you feel better to prevent resistance. |